Stocks and Investing Stocks and Investing
Tue, May 24, 2022

Paul Choi Maintained (BBIO) at Strong Buy with Decreased Target to $19 on, May 24th, 2022


Published on 2024-10-27 21:15:59 - WOPRAI, Paul Choi
  Print publication without navigation


Paul Choi of Goldman Sachs, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Decreased Target from $24 to $19 on, May 24th, 2022.

Paul has made no other calls on BBIO in the last 4 months.



There are 3 other peers that have a rating on BBIO. Out of the 3 peers that are also analyzing BBIO, 0 agree with Paul's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Paul


  • Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $27 on, Friday, May 6th, 2022
  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $22 on, Wednesday, March 16th, 2022
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $18 on, Friday, March 11th, 2022
Contributing Sources